Comparative Pharmacology
Head-to-head clinical analysis: NORPRAMIN versus PRESAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORPRAMIN versus PRESAMINE.
NORPRAMIN vs PRESAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norpramin (desipramine) is a tricyclic antidepressant (TCA) that primarily inhibits the reuptake of norepinephrine, and to a lesser extent serotonin, at the presynaptic neuronal membrane, thereby increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminergic, and alpha1-adrenergic blocking properties.
Predominantly inhibits serotonin reuptake in the presynaptic neuron, increasing serotonin availability in the synaptic cleft. Also inhibits norepinephrine reuptake to a lesser extent.
25 mg orally three times daily; may increase gradually to 150 mg/day in divided doses. Maximum 200 mg/day.
100-300 mg/day orally in divided doses, typically starting at 75 mg/day and titrating upward. Maximum dose 300 mg/day.
None Documented
None Documented
Terminal half-life: 18-34 hours (mean ~27 hours); clinical context: supports once-daily dosing, but steady-state requires 5-7 days.
21 hours (range 16-28 h) for imipramine; active metabolite desipramine ~24 h; clinically, steady-state reached in 5-7 days.
Primarily renal (70%) as metabolites and unchanged drug; biliary/fecal (30%) as metabolites.
Primarily renal (70% as metabolites, <5% unchanged); biliary/fecal (30%).
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant